Jade Biosciences, a portfolio company of RTW Biotech Opportunities (RTW), has merged with Nasdaq-listed Aerovate Therapeutics. The combined business will continue under the name Jade Biosciences, Inc. and trade on Nasdaq under the ticker JBIO. Jade is a privately held biotech firm focused on developing therapies for autoimmune diseases. Its lead candidate, JADE-001, is expected … Continue reading RTW Biotech Opportunities’ Jade Biosciences merges with Aerovate Therapeutics